Surge in Demand for Antiviral Combination Treatment of HIV to Spur Global Antiviral Combination Therapies Market Growth
Antiviral combination therapies are pharmaceutical medications manufactured with the formulation of more than two drugs for treating various viral diseases including hepatitis C, hepatitis B, and Human Immune Deficiency (HIV) virus. The combination antiretroviral treatment concentrates on preventing the spread of the virus further from producing its copies in the human body.
The upsurge in the demand for antiviral combinations specifically for the treatment of HIV patients is the major factor offering momentum to the growth of the global antiviral combination therapies market. Moreover, there is an upsurge in research and development activities for the enhancements in the combination medicines to effectively combat antiviral resistance. The clinical progression of HIV cases is very low in spite of various developments in the combined antiretroviral treatment. The development of effective drug resistance genetic modification plays a vital role in a therapeutic failure and therefore is regarded as difficult to explore a new potent drug combination after treatment failure, which in turn will widen the scope of the market globally. The growing emphasis of market leaders on business entering operations like mergers, joint ventures, and acquisitions will support the growth of the market vigorously.
The global antiviral combination therapies market can be segmented into the distribution channel, indication, drug combination, and region.
By distribution channel, the market can be segmented into retail pharmacies, hospital pharmacies, and others.
By indication, the market can be segmented into hepatitis, HIV, and others. The hepatitis segment accounts for the largest share in the global antiviral combination therapies market.
By drug combination, the market can be segmented into integrase inhibitor, protease inhibitor NTRI, and others. The integrase inhibitor segment holds the domination over others due to the surge in its utilization in HIV care.
North America accounts for the largest share in the global antiviral combination therapies market due to the growing prevalence of hepatitis and HIV infections among the population in the region. Moreover, the high sales of generic drugs associated with HIV infections are generating huge revenue from the region, thereby the region is likely to dominate the global antiviral combination therapies market in the forthcoming years.
Get Sample of this Research Report for more Insights – https://www.zionmarketresearch.com/sample/antiviral-combination-therapies-market
The antiviral combination therapies market is set for a rapid growth over the forecast period. In terms of revenue, the global antiviral combination therapies market accounted for USD 40.94 Billion in 2019 and is expected to reach USD 70.03 Billion by 2026, growing at a CAGR of 7.97%
Asia Pacific is expected to witness a significant growth rate in the forthcoming years due to the constantly growing demand for antiviral combination therapies in the region.
Some of the significant players in the global antiviral combination therapies market are F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Mylan N.V., Cipla, Inc., Johnson & Johnson, Janssen Global Services, Bristol-Myers Squibb Company, AbbVie, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, and Celltrion, Inc. To cite, Ennaid Therapeutics, LLC in April 2020 announced the initiation of the ENU200 production to treat the patients suffering from Covid-19.
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Contact Us –
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651